Anderson S, Brenner BM. Therapeutic benefit of converting enzyme inhibitors in progresive renal disease. Am J Hyper 1988; 1 (suppl): 380-3.

Bakker AJ. Detection of microalbuminuria. Diab Care 1999; 22: 307-313

Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, Steffes MW Striker GE. Screening and Management of Microalbuminuria in patients with Diabetes Mellitus. Am J of Kidney Dis. 1995 (25); 107-112.

Björck S, Mullec H, Johnsen SA et al. Contrsating effects of enalapril and metropolol on proteinuria in diabetic nephropathy. BMJ 1990; 300: 904-7.

Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and the other antihypertensive patients with diabetic nephropathy. AM J Hypertens 1994; 7: 84S-92S.

Borch-Johnsen K, Kofoed-Enevoldeen A, Deckert T. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987; 294: 1651-54.

Cohen DL, Close CF, Viberti GC. The variability of overnight albumin excretion in insulin dependent diabetic and normal subjects. Diabetic Med 1987; 45:343-347.

Deckert T, Feldt-Rasmussen B, Broch-Johsen K, Jensen T. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1988; 32: 219-226.

Gatling W, Knight C, Hill RD: Screening for early diabetic nephropathy: Which sample to detect microalbuminuria? Diabetic Med 1985; 2: 451- 455.

Humphrey LL, Balardd DJ, Frohnert PP, Chu CP, O’Falon WM, Palumbo PJ: Chronic renal failure in non-insulin dependent diabetes mellitus: population-based study in Rochester, Minnesota. Ann Intern Med 1989; 111: 788-796.

Johnston J, Paterson KR, O'Reilly D . Estimating urinary albumin excretion rate of diabetic patients in clinical practice. BMJ 1993; 306: 493-494.

Kasiske BL, Kalil RS, Ma JZ Liao M, Keane WF. Effect of antihypertensive therapy on the kindey in patients with diabetes. A meta-regression analysis. Ann Intern Med 1993; 118: 129-138.

Krolewski AS, Warran JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985; 78: 785-797.

Lewis EJ y col. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Eng J Med 1993; 329: 1456-62

Lovell HG. Are angiotensin converting enzyme inhibitors useful for normotensive diabetic patients with microalbuminuria? ( Cochrane Review). In: The Cochrane Library, Issue 1, 1999. Oxford: Update Software.

Messent JWC, Elliot TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow study. Kidney Int 1992; 41: 836-839.

Mogensen CE. Microalbumnuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J med 1984; 310: 356-360.

Mogensen CE, Vittinghus E. Urinary albumin excretion during exercise in juvenile diabetes. Scand J Lab Invest 1986;35: 295-300.

Mogensen CE, Chacati A, Christensen CK, Close CF, Deckert T, Hommel E et al. Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest 1986; 9: 85-95.

Mogensen CE, Viberti GC, Peheim E, Kutter D, Hasslacher C, Hofman W et al. . Multicentric evaluation of the Micral-test II test strip, an immunologic rapid test for the detection of microalbuminuria. Diab Care 1997; 20: 1642-46.

Molitch ME. ACE inhibitors and diabetic nephropathy. Diabetes Care 1994; 17: 756-59.

Nielsen FS, Rossing P, Gall MA, et al. Comparison of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994; 43: 1108-1113.

Parving HH, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years’ experience. Am J Kidney Dis 1995; 26: 99-107.

Ravid M, Brosh D, Levi Z Bar-Dayan Y, Ravid D Rachmani R et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patiens with type 2 diabetes mellitus. Ann Intern Med 1998; 128: 982-988.

Sawicki Pt, Berger M Measuring progression of diabetic nephropathy. Eur J Clin Invest 1994; 24: 651- 655.

Sirmon MD, Kirkpatrick WG. Diabetic nephropathy: new directions in management. Renal Failure 1991; 13: 51-9.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.

Viberti G, Mogensen CE, Groop LC, Pauls JF.Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-279.

Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos A, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; i: 1430-1432.

Villoria JG, Macias Nuñez JF, Miralles JM De Castro del pozo S, Tabernero Romo JM. Hyporeninemic hypoaldosteronism in diabetic patients with chronic renal failure. Am J Nephrol 1992; 8:127 –137.